Castle Biosciences Inc. has announced that its DecisionDx®-Melanoma test has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). This gene expression profile test is designed to guide risk-aligned management decisions for patients diagnosed with stage I-III cutaneous melanoma by providing personalized insights into a patient's risk of metastasis. The FDA's Breakthrough Device designation is intended to speed up the development and review of devices that offer potential improvements in the treatment or diagnosis of life-threatening conditions. Castle Biosciences plans to submit a device marketing submission to the FDA, aiming to enhance patient care through its innovative test. The grant of this designation is specific to Castle Biosciences, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.